Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings report. Even as the pharmaceutical giant exceeded Wall Street estimates ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

India, Mexico, Brazil, and some other major emerging economies recorded strong growth, while the United States continued to extend its lead as the top destination for direct investment ...

Given high uncertainty around the economic outlook, authorities should stand ready to adjust monetary policy as needed, the Washington-based IMF said in a statement dated February 20. It said ...

The Board of Governors, the highest decision-making body of the IMF, consists of one governor and one alternate governor for each member country. The governor is appointed by the member country and is ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Pakistan had been engaged with the International Monetary Fund (IMF) for acquiring the climate fund and expected $1-1.5 billion support from the global lender, Federal Finance Minister Muhammad ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other pharmaceutical stocks. The Evolving Landscape of Healthcare and Biopharma Innovation ...